<DOC>
	<DOCNO>NCT01456195</DOCNO>
	<brief_summary>The purpose study determine efficacy safety TAK-875 ( fasiglifam ) , daily ( QD ) , participant type 2 diabetes mellitus ( T2DM ) .</brief_summary>
	<brief_title>Comparison TAK-875 ( Fasiglifam ) With Placebo Participants With Type 2 Diabetes</brief_title>
	<detailed_description>TAK-875 develop Takeda Development Center , Inc. adjunct diet exercise improve glycemic control patient T2DM . This study investigate TAK-875 participant type 2 diabetes mellitus treat diet exercise least 12 week prior Screening , take ≤7 day antidiabetic agent within 12 week prior Screening , whose glycemic control inadequate .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>1 . In opinion investigator , participant capable understand comply protocol requirement . 2 . The participant , applicable , participant 's legally acceptable representative sign date write , informed consent form require privacy authorization prior initiation study procedure . 3 . The participant male female 18 year age old historical diagnosis T2DM . 4 . The participant treat diet exercise least 12 week prior Screening HbA1c concentration 7.0 % 10.5 % , inclusive , Screening . 5 . The participant receive ≤7 day antidiabetic agent within 12 week prior Screening . 6 . The participant body mass index ( BMI ) ≤45 kg/m^2 Screening . 7 . Participants regularly use , nonexcluded medication must stable dose least 4 week prior Screening . However , need ( PRN ) use prescription overthecounter medication allow discretion investigator . 8 . The participant able willing monitor glucose home glucose monitor consistently record blood glucose concentration complete participant diary . 9 . A female participant childbearing potential sexually active nonsterilized male partner agree use routinely adequate contraception signing inform consent throughout duration study 30 day last dose study drug . Additional Inclusion Criteria prior Randomization 1 . The participant HbA1c concentration 7.0 10.5 % , inclusive , fast plasma glucose ( FPG ) ≤270 mg/dL ( ≤15.0 mmol/L ) Week 1 Visit . ( If participant qualify randomization base criterion , assessment may repeat weekly , maximum 2 additional week ) . 2 . The participant 's overall compliance singleblind study medication Placebo Runin Period least 75 % exceed 125 % base tablet count perform study staff . 3 . A female participant childbearing potential must negative urine hCG pregnancy test Baseline ( Visit 4 ) prior Randomization prior administration first dose doubleblind study medication 1 . The participant receive investigational compound within 30 day prior Screening receive investigational antidiabetic drug within 3 month prior Screening . 2 . The participant randomize previous TAK875 study . 3 . The participant immediate family member , study site employee , dependent relationship study site employee involve conduct study ( e.g. , spouse , parent , child , sibling ; biological legally adopt ) may consent duress . 4 . The participant donate receive blood product within 12 week prior Screening plan donate blood study . 5 . The participant hemoglobin ≤12 g/dL ( ≤120 gm/L ) males ≤10 g/dL ( ≤100 gm/L ) females Screening . 6 . The participant systolic blood pressure ≥160 mm Hg diastolic blood pressure ≥95 mm Hg Screening ( If participant meet exclusion criterion , assessment may repeat least 30 minute initial measurement decision make base second measurement ) . 7 . The participant history cancer remission &lt; 5 year prior Screening . A history basal cell carcinoma stage 1 squamous cell carcinoma skin allow . 8 . The participant alanine aminotransferase ( ALT ) and/or aspartate aminotransferase ( AST ) level &gt; 2.0x upper limit normal ( ULN ) Screening . 9 . The participant total bilirubin level great ULN Screening . Exception : participant document Gilbert 's Syndrome , participant allow elevated bilirubin level per investigator 's discretion . 10 . The participant serum creatinine ≥1.5 mg/dL ( ≥133 µmol/L ) [ male ] ≥1.4 mg/dL ( ≥124 µmol/L ) [ female ] and/or estimate glomerular filtration rate ( GFR ) &lt; 60 mL/min/1.73m^2 Screening . 11 . The participant uncontrolled thyroid disease . 12 . The participant history laser treatment proliferative diabetic retinopathy within 6 month prior Screening . 13 . The participant gastric band gastric bypass surgery within one year prior Screening . 14 . The participant known history infection human immunodeficiency virus ( HIV ) , Hepatitis B virus ( HBV ) , Hepatitis C virus ( HCV ) . 15 . The participant coronary angioplasty , coronary stent placement , coronary bypass surgery , myocardial infarction , unstable angina pectoris , clinically significant abnormal electrocardiogram ( ECG ) , cerebrovascular accident transient ischemic attack within 3 month prior Screening . 16 . The participant history hypersensitivity , allergy , anaphylactic reaction ( ) component TAK875 . 17 . The participant history drug abuse ( define illicit drug use ) history alcohol abuse within 2 year prior Screening . 18 . The participant receive excluded medication prior Screening expect receive exclude medication . 19 . If female , participant pregnant ( confirmed laboratory testing , i.e. , serum human chorionic gonadotropin ( hCG ) , females childbearing potential ) lactate intend become pregnant , , within 1 month participate study ; intend donate ova time period . 20 . The participant unable understand verbal write English language certify translation approve informed consent available . 21 . The participant physical psychiatric disease condition judgment investigator may affect life expectancy may make difficult successfully manage follow participant accord protocol . Additional Exclusion Criteria prior Randomization 1 . The participant receive excluded medication Placebo Runin Period . ( Topical inhale corticosteroid allow ) . 2 . The participant systolic blood pressure ≥160 mm Hg diastolic blood pressure ≥95 mm Hg Baseline ( Visit 4 ) ( If participant meet exclusion criterion , assessment may repeat least 30 minute initial measurement decision make base second measurement ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Drug Therapy</keyword>
</DOC>